The sequence-specific gene-silencing by small interfering RNA (siRNA) can be used as a new therapeutic approach for treatment of a variety of diseases that are incurable by conventional drugs. Since 2018, FDA has approved 7 siRNA therapeutics and the global siRNA therapeutics market is expected to embark on an exponential growth to reach US$24.16 billion at a CAGR of 17.5 in 2026.
However, siRNA therapeutics suffer from two severe shortcomings that has continued to inhibit their widespread applications, which are (1) poor stability in physiological conditions and (2) induction of unwanted off-target effects. Our disruptive solution is a bioengineering technology that overcomes these shortcomings by the engineering of a polymeric nanoplex with tunable electrostatic (surface charge) properties that provides both siRNA protection against instability and cell-targeting properties. This technology has been demonstrated via proof-of-concept (POC) to be safe and effective in scar treatment in animal models (rabbit eye glaucoma and mouse wound models) and human. The global scar therapy market is valued at US$21 billion at 2021 with a CAGR of 10%.
This talk will discuss the mechanism of siRNA gene silencing based on the current polymeric platform, animal studies, patient studies and its commercialization via a Singapore spin-of RNAscence BioTech Pte Ltd. The current siRNA nanoplex platform can also be applied to a wide range of clinical and health conditions, targeting fibrotic and inflammatory diseases such as pulmonary inflammation (e.g. acute lung infection due to Covid 19), cancer, pathological scars arising from burns and skin trauma, eczema, melasma (skin pigmentation), etc.